STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Abivax S.A. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Venrock-affiliated funds filed Amendment No. 2 to Schedule 13G reporting a passive stake in Abivax SA (ABVX). The group reported beneficial ownership of 576,729 ordinary shares in the form of ADSs, representing 0.8% of the class as of September 30, 2025.

The holdings comprise 151,622 ADSs by VHCP III, 15,167 ADSs by VHCP Co-Investment III, and 409,940 ADSs by VHCP EG. Each ADS represents one ordinary share. The percentage was calculated against 73,574,749 ordinary shares outstanding as of July 28, 2025, per the issuer’s prospectus supplement. The reporting persons disclose shared voting and dispositive power over 576,729 shares and no sole power. They certified the securities were not acquired to change or influence control.

Positive
  • None.
Negative
  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Venrock Healthcare Capital Partners III, L.P.
Signature:/s/ Sherman G. Souther
Name/Title:By VHCP Management II, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
Date:11/14/2025
VHCP Co-Investment Holdings III, LLC
Signature:/s/ Sherman G. Souther
Name/Title:By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
Date:11/14/2025
Venrock Healthcare Capital Partners EG, L.P.
Signature:/s/ Sherman G. Souther
Name/Title:By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
Date:11/14/2025
VHCP Management III, LLC
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Authorized Signatory
Date:11/14/2025
VHCP Management EG, LLC
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Authorized Signatory
Date:11/14/2025
Nimish Shah
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Attorney-in-fact
Date:11/14/2025
Bong Y. Koh
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Attorney-in-fact
Date:11/14/2025
Exhibit Information

Exhibit 24.1 Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed November 22, 2023) Exhibit 24.2 Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on November 22, 2023) Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on November 22, 2023)

FAQ

What did Venrock report in the ABVX Schedule 13G/A?

Beneficial ownership of 576,729 Abivax ordinary shares (via ADSs), equal to 0.8% of the class, in an Amendment No. 2 filing.

How many ABVX shares and what percentage are reported?

A total of 576,729 ordinary shares (ADSs), representing 0.8% of Abivax’s outstanding shares.

How is the ABVX stake held by the Venrock entities?

VHCP III holds 151,622 ADSs; VHCP Co-Investment III holds 15,167 ADSs; VHCP EG holds 409,940 ADSs. Each ADS equals one ordinary share.

What date does the ownership information reflect?

The ownership figures are stated as of September 30, 2025.

What share count was used to calculate the 0.8% figure for ABVX?

The calculation is based on 73,574,749 ordinary shares outstanding as of July 28, 2025.

Do the reporting persons have voting or dispositive power over ABVX shares?

They report shared voting and shared dispositive power over 576,729 shares and no sole power.

Did the filers indicate an intent to influence control at Abivax?

They certified the securities were not acquired and are not held to change or influence control.
Abivax S.A.

NASDAQ:ABVX

ABVX Rankings

ABVX Latest News

ABVX Latest SEC Filings

ABVX Stock Data

7.85B
77.83M
43.25%
2.15%
Biotechnology
Healthcare
Link
France
Paris